Management of Chronic Hand Eczema.

Abstract

Management of hand eczema is complex because of the broad range of different pathogeneses, courses, and prognoses. Furthermore, the efficacy of most available treatments is not well established and the more severe forms can have a major impact on the patient's quality of life. Patient education, preventive measures, and the use of emollients are the mainstays in the management of hand eczema. High-potency topical corticosteroids are the treatment of choice, with calcineurin inhibitors used for maintenance. Phototherapy or systemic treatments are indicated in patients who do not respond to topical treatments. Switching from topical treatments should not be delayed to avoid sensitizations, time off work, and a negative impact on quality of life. Alitretinoin is the only oral treatment approved for use in chronic hand eczema.

• Authors: F J de León, L Berbegal, J F Silvestre
• Journal: Actas dermo-sifiliograficas (Actas Dermosifiliogr) Vol. 106 Issue 7 Pg. 533-44 (Sep 2015) ISSN: 1578-2190 [Electronic] Spain
• PMID: 26005193 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2015 Elsevier España, S.L.U. and AEDV. All rights reserved.

Chemical References

• Adrenal Cortex Hormones
• Calcineurin Inhibitors
• Dermatologic Agents
• Emollients
• Immunosuppressive Agents
• Alitretinoin
• Tretinoin

Topics

• Adrenal Cortex Hormones (therapeutic use)
• Alitretinoin
• Calcineurin Inhibitors (therapeutic use)
• Chronic Disease
• Combined Modality Therapy
• Dermatitis, Contact (drug therapy, prevention & control, therapy)
• Dermatologic Agents (therapeutic use)
• Disease Management
• Eczema (drug therapy, prevention & control, therapy)
• Emollients (therapeutic use)
• Gloves, Protective
• Hand Dermatoses (drug therapy, prevention & control, therapy)
• Humans
• Immunosuppressive Agents (therapeutic use)
• Occupational Diseases (drug therapy, prevention & control, therapy)
• Phototherapy
• Practice Guidelines as Topic
• Quality of Life
• Tretinoin (therapeutic use)